Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Lung Cancer In Women: Exploring Sex Differences In Susceptibility, Biology, And Therapeutic Response.
J. Donington, Q. Le, H. Wakelee
Published 2006 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Src tyrosine kinases regulate a large number of important mechanisms in normal and cancerous cells, are overexpressed in a broad range of tumors including lung cancer, and thus represent a potential target for cancer therapy. Preclinical experiments indicate that small-molecule inhibitors of Src block tumor growth, metastasis, and angiogenesis. Phase I data from healthy volunteers also suggest that inhibitors of Src prevent bone resorption. Several phase II trials with small-molecule inhibitors of Src are under way or have been initiated in lung cancer and in other malignancies, as discussed herein.
This paper references
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
F. Fossella (2003)
Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases.
E. Radzikowska (2002)
O-207 Collateral damage from the lung cancer explosion in American women: Has sex migration replaced stage migration as a confounding factor in lung cancer trials?
J. Patel (2003)
Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.
H. West (2006)
Gender and histologic type variations in smoking-related risk of lung cancer.
R. Brownson (1992)
Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers
M. Wong (2003)
Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol.
D. Ignar-Trowbridge (1996)
Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features
Sanford H. Barsky (1994)
Restoration of aryl hydrocarbon (Ah) responsiveness in MDA-MB-231 human breast cancer cells by transient expression of the estrogen receptor.
J. Thomsen (1994)
Re: Endocrine factors and adenocarcinoma of the lung in women.
E. Taioli (1994)
Implications and prognostic value of K-ras mutation for early-stage lung cancer in women.
H. Nelson (1999)
Genetic susceptibility to tobacco carcinogenesis.
M. Spitz (1999)
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
K. Albain (1995)
Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas.
T. Mclemore (1990)
The ErbB signaling network: receptor heterodimerization in development and cancer
M. Olayioye (2000)
Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival.
M. Werner-wasik (2000)
Lung cancer in women: emerging differences in epidemiology, biology, and therapy.
Leno Thomas (2005)
Sex-associated differences in presentation and survival in patients with lung cancer.
M. Ferguson (1990)
Sex differences in lung‐cancer risk associated with cigarette smoking
K. Osann (1993)
Molecular Mechanisms of Estrogen Carcinogenesis
Yager Jd (1996)
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
M. Kris (2003)
Reducing the Health Consequences of Smoking: 25 Years of Progress. A Report of the Surgeon General.
R. Heidel (1989)
Somatostatin analogue SMS 201–995 (octreotide) as a possible solution to the dumping syndrome after gastrectomy or vagotomy
J. Primrose (1989)
p21ras: an oncoprotein functioning in growth factor-induced signal transduction.
J. Bos (1995)
Glutathione S-transferases: gene structure and regulation of expression.
V. Daniel (1993)
A pooled analysis of 11 NCCTG advanced stage non-small cell lung cancer (NSCLC) trials reveals the importance of baseline blood counts on clinical outcomes
S. Mandrekar (2005)
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
Ming-Sound Tsao (2005)
Epidemiology of tobacco use in the United States
G. Giovino (2002)
High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan
S. Huang (2004)
P-452 Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): Analyses by gender
C. Belani (2005)
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
R. Lord (2002)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
T. Lynch (2004)
Hormone Replacement Therapy and Lung Cancer Risk
M. Schabath (2004)
k-ras mutation and occupational asbestos exposure in lung adenocarcinoma: asbestos-related cancer without asbestosis.
H. Nelson (1999)
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
J. Rossouw (2002)
p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels.
E. Kure (1996)
Variation in smoking-related lung cancer risk among New Jersey women.
J. Schoenberg (1989)
Tamoxifen does not reduce the risk of lung cancer in women
J. Patel (2005)
Risk of cancer in women receiving hormone replacement therapy
H. Adami (1989)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
M. Fukuoka (2003)
Changes in the natural history of nonsmall cell lung cancer (NSCLC)—Comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990
H. Wakelee (2006)
Prognostic factors for patients with small cell lung carcinoma
M. Paesmans (2000)
Human Non-Small Cell Lung Tumors and Cells Derived from Normal Lung Express Both Estrogen Receptor α and β and Show Biological Responses to Estrogen
L. Stabile (2002)
DNA adducts, mutations and cancer.
K. Hemminki (1993)
O-104 XYOTAXT™ vs. gemcitabine or vinorelbine for the treatment of performance status (PS) 2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): The STELLAR 4 Phase III study
M. O'Brien (2005)
Lung cancer in women: sex-associated differences in survival of patients undergoing resection for lung cancer.
H. Minami (2000)
Tobacco or health: a WHO programme.
C. Chollat-Traquet (1992)
Regulation of Postnatal Lung Development and Homeostasis by Estrogen Receptor β
Cesare Patrone (2003)
Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base.
K. Albain (1990)
Weight concerns, dieting behavior, and smoking initiation among adolescents: a prospective study.
S. French (1994)
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
J. Paez (2004)
Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma.
M. D. de Perrot (2000)
Incidence of ras oncogene activation in lung carcinomas in Hong Kong
M. Lung (1992)
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.
K. Albain (1991)
Are Smoking‐Associated Cancers Prevented or Postponed in Women Using Hormone Replacement Therapy?
H. Olsson (2003)
Gender differences in genetic susceptibility for lung cancer.
C. Dresler (2000)
Reduced Mortality Associated With Long‐Term Postmenopausal Estrogen Therapy
B. Ettinger (1996)
Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002.
A. Visbal (2004)
Prognostic value of loss of heterozygosity and KRAS2 mutations in lung adenocarcinoma
L. De Gregorio (1998)
Estrogen replacement therapy and risk of lung cancer
J. A. Blackman (2002)
Phase I and II carcinogen metabolism gene expression in human lung tissue and tumors.
S. Spivack (2003)
Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer.
S. P. Shriver (2000)
Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane
J. Singer (2005)
Lung cancer rates in men and women with comparable histories of smoking.
C. Bain (2004)
Carotenoid intake, vegetables, and the risk of lung cancer among white men in New Jersey.
R. Ziegler (1986)
Sex differences in risk of lung cancer: Expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts
S. Mollerup (2006)
Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer.
D. Bell (1993)
Female patients with small cell lung cancer live longer than male patients.
B. Johnson (1988)
Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern
E. Enmark (1997)
Women's susceptibility to tobacco carcinogens.
C. Henschke (2004)
Detection of K-ras mutations in lung carcinomas: relationship to prognosis.
P. Keohavong (1996)
Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type.
H. Risch (1993)
Contemporary Lung Cancer Trends among U.S. Women
A. Jemal (2005)
ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis.
K. Sugio (1992)
Longer survival after resection of non-small cell lung cancer in Japanese women.
T. Mitsudomi (1989)
Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung.
R. J. Slebos (1991)
Cytosine methylation determines hot spots of DNA damage in the human P53 gene.
M. Denissenko (1997)
Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow up study.
J. Seidegård (1990)
Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.
M. Paesmans (1995)
Survival Differences by Sex for Patients with Advanced Non-small Cell Lung Cancer on Eastern Cooperative Oncology Group Trial 1594
H. Wakelee (2006)
Cancer Statistics, 2006
A. Jemal (2006)
Women and smoking: a report of the Surgeon General.
D. Satcher (2002)
Expression, Function, and Clinical Implications of the Estrogen Receptor β in Human Lung Cancers
Y. Omoto (2001)
Gender differences in lung cancer risk by smoking: a multicentre case–control study in Germany and Italy
M. Kreuzer (2000)
Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern.
E. Enmark (1997)
Differences in lung cancer risk between men and women: examination of the evidence.
E. Zang (1996)
The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer.
S. Keller (2002)
Relationships between DNA adduct formation and carcinogenesis.
J. Swenberg (1985)
The CYP1A1 gene and cancer susceptibility.
K. Kawajiri (1993)
Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study.
Q. Wei (2000)
Variations in lung cancer risk among smokers.
P. Bach (2003)
Biological action of catechol oestrogens.
J. Fishman (1981)
This paper is referenced by
Lung cancer, smoke exposure, and sex.
A. Gazdar (2007)
Do Female Cancer Patients Display Better Survival Rates Compared with Males? Analysis of the Korean National Registry Data, 2005–2009
K. Jung (2012)
Sex differences in lung-cancer susceptibility: a smoke screen?
H. Wakelee (2008)
Progesterone and estrogen prevent cisplatin-induced apoptosis of lung cancer cells.
M. Grott (2013)
The prognostic impact of the amount of tobacco smoking in non-small cell lung cancer--differences between adenocarcinoma and squamous cell carcinoma.
T. Okamoto (2014)
Mechanisms of Disease: signal transduction in lung carcinogenesis—a comparison of smokers and never-smokers
G. Mountzios (2008)
Die künftige Entwicklung der Erkrankungszahlen von Darmkrebs und Lungenkrebs
E. Nowossadeck (2013)
The Significance of Visceral Pleural Surface Invasion in 321 Cases of Non-Small Cell Lung Cancers with Pleural Retraction
Y. Chang (2012)
[Gender-associated differences of lung cancer and mechanism].
X. Xing (2011)
Smoking and Pancreatic Cancer Incidence: A Pooled Analysis of 10 Population-Based Cohort Studies in Japan
Y. Koyanagi (2019)
Radon risk in carcinogenesis what prevention
Mauro Mazzotta (2020)
Epidemiology of Lung Cancer
D. Repana (2017)
Gender Differences in Lung Cancer Treatment and Survival
M. Kowski (2011)
Lung cancer incidence in never smokers.
H. Wakelee (2007)
Population aging and hospitalization for chronic disease in Germany.
E. Nowossadeck (2012)
A practical and adaptive approach to lung cancer screening: a review of international evidence and position on CT lung cancer screening in the Singaporean population by the College of Radiologists Singapore.
C. Liew (2019)
Disparities in Lung Cancer Outcomes
Ching-Fei Chang (2016)
Long‐term exposure to fine particulate matter air pollution and the risk of lung cancer among participants of the Canadian National Breast Screening Study
A. Tomczak (2016)
Lung cancer and women.
S. Novello (2008)
Outcome and treatment strategy in female lung cancer: a single institution experience.
S. Cicėnas (2010)